<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01689181</url>
  </required_header>
  <id_info>
    <org_study_id>C11-39</org_study_id>
    <secondary_id>2011-A01610-41</secondary_id>
    <nct_id>NCT01689181</nct_id>
  </id_info>
  <brief_title>Apathy in Schizophrenia</brief_title>
  <official_title>L'Apathie Dans la schizophrénie: étude Neuropsychologique et Anatomique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apathy, defined as a quantitative reduction of voluntary, goal-directed behaviours (GDB), is&#xD;
      a core component of negative symptoms. It has been suggested that the physiopathology of&#xD;
      apathy is not a single entity but may be multiple, depending on which specific process or&#xD;
      macrofunction is disrupted during completion of GDB. In line with this notion, Levy and&#xD;
      Dubois proposed dividing apathic syndromes into three subtypes of disrupted processing:&#xD;
      'a-motivation', 'cognitive inertia', and 'uncoupling'. In schizophrenia, apathy has been&#xD;
      associated with executive dysfunction, functional impairment and poor outcome. However, the&#xD;
      neurobiological underpinnings of apathy in schizophrenia are poorly understood.&#xD;
&#xD;
      Primary objective: confirm that chronic schizophrenic patients are apathic compared to&#xD;
      healthy volunteers&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  investigate if apathy is related to a particular aspect of the disease (i.e. negative,&#xD;
           positive symptomatology and/or deficit form)&#xD;
&#xD;
        -  investigate if apathy correlates with executive dysfunction&#xD;
&#xD;
        -  investigate if apathy is associated with a specific mechanism using an experimental task&#xD;
           specially designed to investigate the different mechanism (i.e. 'a-motivation',&#xD;
           'cognitive inertia', and 'uncoupling')&#xD;
&#xD;
        -  investigate if there is a volumetric abnormality affecting the executive system in&#xD;
           apathic schizophrenic patients&#xD;
&#xD;
        -  link these eventual volumetric abnormalities to prefrontal cortex-basal ganglia circuits&#xD;
           according to a specific subtype of apathy in the apathic schizophrenic group&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>apathy as measured by Starkstein's Apathy Evaluation Scale</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>neuropsychological performance</measure>
    <time_frame>baseline</time_frame>
    <description>Global mental efficience: Mill Hill B and Raven's progressive matrices 38&#xD;
Executive functioning:Modified Card Sorting Test, Trail Making A and B, Stroop Test, Verbal Fluences, Frontal Assessment Battery (FAB, Dubois et al., 2000)&#xD;
Social and Emotional Cognition: SEA (Social and Emotional Evaluation (SEA, Funkiewiez et al., 2012)&#xD;
Working memory (Grober and Buschke - 16 items, digit span)&#xD;
Instrumental functions: Rey Osterrieth Complex figure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical assessment (for patients only)</measure>
    <time_frame>baseline</time_frame>
    <description>scores on evaluation scales (PANSS, SAPS, SANS, CDS, SDS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>volumetric brain abnormalities</measure>
    <time_frame>baseline</time_frame>
    <description>voxel based morphometry</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Apathy</condition>
  <arm_group>
    <arm_group_label>chronic schizophrenic patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        schizophrenic patients:&#xD;
&#xD;
          -  outpatients of the Corentin Celton psychiatric service&#xD;
&#xD;
          -  inpatients of the Corentin Celton Day Hospital Unit&#xD;
&#xD;
        healthy volunteers: community&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (healthy volunteers):&#xD;
&#xD;
          -  Male or Female aged 20 to 55 years old included&#xD;
&#xD;
          -  Under French public assurance system&#xD;
&#xD;
        Exclusion Criteria (healthy volunteers):&#xD;
&#xD;
          -  Personal history of neurological disorders&#xD;
&#xD;
          -  Personal history of head injury&#xD;
&#xD;
          -  Alcohol or substance abuse&#xD;
&#xD;
          -  Under psychotropic drug&#xD;
&#xD;
          -  Contraindication for MRI&#xD;
&#xD;
        Inclusion Criteria (schizophrenic patients):&#xD;
&#xD;
          -  Male or Female aged 20 to 55 years old included&#xD;
&#xD;
          -  Under French public assurance system&#xD;
&#xD;
          -  diagnosis of schizophrenia according to the DSM-IV R criteria&#xD;
&#xD;
          -  Duration of illness &gt; 5 years&#xD;
&#xD;
          -  clinical stability during the past 2 months (defined as no treatment modification or&#xD;
             hospitalisation 2 months prior evaluation)&#xD;
&#xD;
        Exclusion Criteria (schizophrenic patients):&#xD;
&#xD;
          -  Schizo-affective disorder&#xD;
&#xD;
          -  Personal history of neurological disorders&#xD;
&#xD;
          -  Personal history of head injury&#xD;
&#xD;
          -  Alcohol or substance abuse&#xD;
&#xD;
          -  Contraindication for MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Levy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>INSERM MEDU 945, Centre de Recherche-Institut du Cerveau et de la Moelle (CR-ICM), Hôpital de la Pitié Salpétrière, 75013 Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard LEVY, MD/PHD</last_name>
    <phone>00.33.1.49.28.24.32</phone>
    <email>richard.levy@sat.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>INSERM MEDU 945, Centre de Recherche-Institut du Cerveau et de la Moelle (CR-ICM), Hôpital de la Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>September 7, 2012</study_first_submitted>
  <study_first_submitted_qc>September 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2012</study_first_posted>
  <last_update_submitted>September 17, 2012</last_update_submitted>
  <last_update_submitted_qc>September 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

